Host-Based Treatments for Severe COVID-19
-
Published:2023-04-05
Issue:4
Volume:45
Page:3102-3121
-
ISSN:1467-3045
-
Container-title:Current Issues in Molecular Biology
-
language:en
-
Short-container-title:CIMB
Author:
Mondini Lucrezia1ORCID, Salton Francesco1ORCID, Trotta Liliana1, Bozzi Chiara1, Pozzan Riccardo1, Barbieri Mariangela1, Tavano Stefano1, Lerda Selene2, Hughes Michael3, Confalonieri Marco1ORCID, Confalonieri Paola1ORCID, Ruaro Barbara1ORCID
Affiliation:
1. Pulmonology Unit, Department of Medical Surgical and Health Sciences, University Hospital of Cattinara, University of Trieste, 34149 Trieste, Italy 2. Graduate School, University of Milan, 20149 Milano, Italy 3. Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester & Salford Royal NHS Foundation Trust, Manchester M6 8HD, UK
Abstract
COVID-19 has been a global health problem since 2020. There are different spectrums of manifestation of this disease, ranging from asymptomatic to extremely severe forms requiring admission to intensive care units and life-support therapies, mainly due to severe pneumonia. The progressive understanding of this disease has allowed researchers and clinicians to implement different therapeutic alternatives, depending on both the severity of clinical involvement and the causative molecular mechanism that has been progressively explored. In this review, we analysed the main therapeutic options available to date based on modulating the host inflammatory response to SARS-CoV-2 infection in patients with severe and critical illness. Although current guidelines are moving toward a personalised treatment approach titrated on the timing of presentation, disease severity, and laboratory parameters, future research is needed to identify additional biomarkers that can anticipate the disease course and guide targeted interventions on an individual basis.
Subject
Microbiology (medical),Molecular Biology,General Medicine,Microbiology
Reference79 articles.
1. (2023, February 13). Timeline: WHO’s COVID-19 Response. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline. 2. (2023, February 13). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/. 3. ARDS Definition of Task Force, Ranieri, V.M., Rubenfeld, G.D., Thompson, B.T., Ferguson, N.D., Caldwell, E., Fan, E., Camporota, L., and Slutsky, A.S. (2012). Acute respiratory distress syndrome: The Berlin Definition. JAMA, 307, 2526–2533. 4. World Health Organization (2023). Therapeutics and COVID-19: Living Guideline, 13 January 2023, World Health Organization. WHO/2019-nCoV/therapeutics/2023.1. 5. Pelosi, P., Tonelli, R., Torregiani, C., Baratella, E., Confalonieri, M., Battaglini, D., Marchioni, A., Confalonieri, P., Clini, E., and Salton, F. (2022). Different Methods to Improve the Monitoring of Noninvasive Respiratory Support of Patients with Severe Pneumonia/ARDS Due to COVID-19: An Update. J. Clin. Med., 11.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|